Veeva Sees 20% Subscription Growth, $6 Billion Revenue Goal by 2030
Veeva Systems generated $2.75 billion in FY25 revenue, growing mid-teens year-on-year with subscription revenue up ~20% while professional services remained constrained to protect margins. Management targets roughly $6 billion in revenue by 2030—two-thirds from R&D solutions and one-third from commercial offerings—supported by expanding recurring subscriptions and high switching costs.
1. Revenue Performance and Growth Targets
Veeva delivered $2.75 billion in FY25 revenue, up mid-teens year-over-year, driven by a 20% increase in subscription sales while intentionally constraining professional services to preserve margins. Management forecasts scaling to ~$6 billion by 2030, with two-thirds of revenue from R&D solutions and one-third from commercial offerings.
2. Product Expansion and Recurring Model
The company continues building new modules across clinical data management, quality systems, regulatory intelligence, safety, patient and HCP engagement, and data-driven commercialization to deepen wallet share in large biopharma and adjacent segments. Its multitenant Vault platform embeds domain expertise and compliance, reinforcing its high-margin, sticky subscription model.
3. CRM Migration Strategy
Veeva is migrating its legacy Salesforce-based CRM to Vault CRM, with over 115 customers live, including top 20 pharma firms. This transition aims to reduce platform dependency, drive customer innovation, and maintain CRM revenue share expected to decline from 20% in 2025 to 10% by 2030, introducing execution risks in large global deployments.
4. Competitive Landscape and Risks
High switching costs from data migration, validation requirements, and process reconfiguration underpin Veeva’s pricing power but also expose the company to negotiating leverage from sophisticated pharma clients. Regulatory changes, horizontal platform competition and the premium valuation multiple pose risks to future growth and stock performance.